Evidence map›Paper›PMID 40370262›Full record

ArticleEuropean journal of haematology2025

Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.

Laurène Fenwarth, Benjamin Podvin, Loïc Vasseur, Delphine Lebon, Guillaume Couillez, Céline Berthon, Alexis Caulier, Elise Fournier, Claire Bories, Benjamin Carpentier and 14 more

Abstract read
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Laurène FenwarthLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.ORCID https://orcid.org/0000-0003-2808-4843
Benjamin PodvinLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.ORCID https://orcid.org/0000-0002-0616-8694
Loïc VasseurDepartment of Hematology, Saint Louis Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0000-0001-9065-0477
Delphine LebonDepartment of Hematology, CHU Amiens-Picardie, Amiens, France.
Guillaume CouillezLaboratory of Hematology, CHU Amiens-Picardie, Amiens, France.
Céline BerthonUniv. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Alexis CaulierDepartment of Hematology, CHU Amiens-Picardie, Amiens, France.
Elise FournierLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.
Claire BoriesDepartment of Hematology, CH Lens, Lens, France.
Benjamin CarpentierDepartment of Hematology, St Vincent Hospital, Lille, France.
Sabine TricotDepartment of Hematology, CH Valenciennes, Valenciennes, France.
Kevin-James WattebledDepartment of Hematology, CH Dunkerque, Dunkerque, France.
Catherine Roche-LestienneUniv. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Valentin LestringantLaboratory of Hematology, CHU Amiens-Picardie, Amiens, France.
Carine HauspieLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.
Karine Celli-LebrasDepartment of Hematology, Saint Louis Hospital, AP-HP, Paris, France.
Maël HeibligDepartment of Hematology, Hospices Civils de Lyon, Lyon, France.
Hervé DombretDepartment of Hematology, Saint Louis Hospital, AP-HP, Paris, France.
Raphael ItzyksonDepartment of Hematology, Saint Louis Hospital, AP-HP, Paris, France.
Jean-Pierre MarolleauDepartment of Hematology, CHU Amiens-Picardie, Amiens, France.
Loïc GarçonLaboratory of Hematology, CHU Amiens-Picardie, Amiens, France.
Claude PreudhommeLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.
Nicolas DuployezLaboratory of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.ORCID https://orcid.org/0000-0002-3927-1022
Thomas BoyerLaboratory of Hematology, CHU Amiens-Picardie, Amiens, France.ORCID https://orcid.org/0000-0001-8133-5491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evolution of acute myeloid leukemia (AML) classifications has progressively shifted the diagnostic focus toward genetic criteria. Nevertheless, morphology remains a key element in clinical practice, often serving as the initial trigger for additional molecular investigations. The diagnosis of acute erythroleukemia (AEML), initially defined by the FAB group, is no longer recognized as a distinct entity in the latest WHO and ICC classifications. Some studies have indicated that AEML shares similarities with myelodysplastic neoplasms, including a high frequency of TP53 mutations and adverse karyotypes. Here, we conducted a retrospective analysis in adults with AEML defined using historical morphologic criteria (≥ 50% erythroid precursors and ≥ 20% blasts among non-erythroid cells). In contrast to older patients, young adults (18-60 years) exhibit unique genetic profiles including a high prevalence of normal karyotypes (65%), NPM1 (35%) and UBTF (23%) mutations. AEML morphology in NPM1-mutated cases did not impact clinical outcomes but was associated with specific molecular features, including an enrichment of WT1 and cohesin gene mutations. In this age group, our findings support that morphologically defined AEML often corresponds to AML according to current genetic criteria, consistent with recent classification systems that prioritize molecular features over morphology.

Indexed as

Leukemia, Erythroblastic, AcuteAdolescentAdultAgedAge FactorsBiomarkers, TumorFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNucleophosminRetrospective StudiesYoung AdultBiomarkers, TumorNPM1 protein, humanNucleophosminAMLclassificationerythroleukemiaNPM1UBTF

Identifiers

PMID40370262
PMCPMC12224554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.